| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/AJH.24543 |
| P698 | PubMed publication ID | 27563744 |
| P50 | author | Stacy E Croteau | Q59787483 |
| Jan Hartmann | Q64140789 | ||
| P2093 | author name string | Jan Hartmann | |
| Stacy E Croteau | |||
| P2860 | cites work | New insights into the biology of tissue factor pathway inhibitor | Q26865048 |
| FVIII inhibitors: pathogenesis and avoidance | Q27027224 | ||
| Progress and challenges in the development of a cell-based therapy for hemophilia A | Q27027298 | ||
| How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors | Q28084000 | ||
| Gene therapy in an era of emerging treatment options for hemophilia B | Q28087557 | ||
| Tissue factor pathway inhibitor: structure, biology and involvement in disease | Q28279765 | ||
| Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity | Q28487387 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. | Q30429771 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| How we choose factor VIII to treat hemophilia | Q34260815 | ||
| The hemophilias--from royal genes to gene therapy | Q34276237 | ||
| BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B | Q34348566 | ||
| A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. | Q34503723 | ||
| Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. | Q34528148 | ||
| Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia | Q34661163 | ||
| Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial | Q34737483 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Comparative effectiveness of full‐length and B‐domain deleted factor VIII for prophylaxis – a meta‐analysis | Q35106858 | ||
| The epidemiology of inhibitors in haemophilia A: a systematic review | Q35163634 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Females with FVIII and FIX deficiency have reduced joint range of motion | Q35771219 | ||
| Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A | Q36000862 | ||
| Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity | Q36166303 | ||
| Strategies towards a longer acting factor VIII. | Q36473043 | ||
| Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia | Q36473047 | ||
| Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates | Q36533097 | ||
| New treatments in hemophilia: insights for the clinician | Q36612681 | ||
| PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies | Q36614270 | ||
| Adeno-associated viral vectors for the treatment of hemophilia. | Q36713767 | ||
| Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial | Q36780134 | ||
| International workshop on immune tolerance induction: consensus recommendations | Q36861097 | ||
| Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s | Q37098836 | ||
| CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse | Q37446641 | ||
| Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. | Q37489013 | ||
| Cost of care of haemophilia with inhibitors. | Q37618924 | ||
| Factor V Leiden and hemophilia | Q37637223 | ||
| Recent advances in lentiviral vector development and applications | Q37678176 | ||
| Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice | Q37690441 | ||
| Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. | Q37767264 | ||
| Women and bleeding disorders | Q37768884 | ||
| Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia | Q37781837 | ||
| Hemostatic properties of a TFPI antibody | Q37992303 | ||
| PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. | Q38036746 | ||
| Importance of pharmacokinetics in the management of hemophilia | Q38056463 | ||
| Hemophilia clinical gene therapy: brief review | Q38076953 | ||
| Considerations in individualizing prophylaxis in patients with haemophilia A. | Q38203021 | ||
| Turoctocog alfa (NovoEight®)--from design to clinical proof of concept | Q38209486 | ||
| Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein | Q38316749 | ||
| Role of enhanced half-life factor VIII and IX in the treatment of haemophilia | Q38371071 | ||
| Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). | Q38418489 | ||
| Obstacles and future of gene therapy for hemophilia | Q38529941 | ||
| Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials | Q38590269 | ||
| A critical appraisal of one-stage and chromogenic assays of factor VIII activity | Q38668506 | ||
| Gene therapy for hemophilia: past, present and future | Q38710080 | ||
| Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph. | Q38796239 | ||
| Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. | Q38818573 | ||
| Genetic Targeting of the Albumin Locus to Treat Hemophilia | Q40826846 | ||
| Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. | Q40876006 | ||
| Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein | Q41611929 | ||
| Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies | Q41664760 | ||
| Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. | Q41975229 | ||
| Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia | Q42360054 | ||
| A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study | Q42598903 | ||
| Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response | Q42921117 | ||
| A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. | Q43690317 | ||
| A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice | Q43919575 | ||
| Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors | Q44258968 | ||
| A study of reported factor VIII use around the world | Q44855946 | ||
| Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization | Q45838031 | ||
| Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. | Q45858690 | ||
| Codon optimization of human factor VIII cDNAs leads to high-level expression | Q45864601 | ||
| Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. | Q45868033 | ||
| Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. | Q45869805 | ||
| Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial | Q45872638 | ||
| An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. | Q45874701 | ||
| Transition considerations for extended half-life factor products. | Q45874821 | ||
| The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. | Q45876258 | ||
| Targeting Antithrombin to Treat Hemophilia | Q45877933 | ||
| Guidelines for the management of hemophilia | Q45880345 | ||
| A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model | Q45882197 | ||
| Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. | Q45882349 | ||
| Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. | Q45884927 | ||
| von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo | Q45886092 | ||
| Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats. | Q53188317 | ||
| P433 | issue | 12 | |
| P921 | main subject | hemophilia | Q134003 |
| P304 | page(s) | 1252-1260 | |
| P577 | publication date | 2016-08-26 | |
| P1433 | published in | American Journal of Hematology | Q4744246 |
| P1476 | title | 2017 Clinical trials update: Innovations in hemophilia therapy. | |
| P478 | volume | 91 |
| Q38671280 | ASH Meeting 2016: developments in hemostaseology. |
| Q92593042 | An Interesting Case of Acquired Hemophilia A in an Elderly Patient Presenting with Hematuria |
| Q58800521 | An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs |
| Q45872816 | Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma |
| Q89676767 | Direct Cytosolic Delivery of Proteins through Coengineering of Proteins and Polymeric Delivery Vehicles |
| Q92341122 | Efficient nanocarriers of siRNA therapeutics for cancer treatment |
| Q91947550 | Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII) |
| Q90262136 | From the voices of people with haemophilia A and their caregivers: Challenges with current treatment, their impact on quality of life and desired improvements in future therapies |
| Q51057724 | Gene Therapy for Hemophilia. |
| Q47225946 | Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice |
| Q57083979 | Gene therapy in hemophilia A: a cost-effectiveness analysis |
| Q41928233 | Genome engineering: a new approach to gene therapy for neuromuscular disorders. |
| Q45874959 | Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions |
| Q38764214 | Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products |
| Q60302918 | Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A |
| Q51759036 | Small Molecule Catalysts with Therapeutic Potential. |
| Q96348307 | Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia |
| Q47215919 | Targeting anticoagulant protein S to improve hemostasis in hemophilia. |
| Q47697767 | The impact of extended half-life versus conventional factor product on hemophilia caregiver burden |
| Q64326173 | The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries |
| Q90595648 | Update on clinical gene therapy for hemophilia |
Search more.